Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.
BACKGROUND
The aim of this study was to examine the effect of magnesium supplementation on nephrotoxicity accompanying standard cisplatin-based chemotherapy in patients with epithelial ovarian cancer (EOC).


METHODS
A double-blind, placebo-controlled, randomised study was conducted in which study arm magnesium sulphate (5 g) was administered before each course of standard chemotherapy with paclitaxel (135 mg/m(2)/24 h) plus cisplatin (75 mg/m(2)) every 3 weeks in patients with EOC. Magnesium subcarbonate (500 mg), three times per day orally, was administered during the treatment intervals. The control arm was administered a placebo instead of both magnesium salts. Magnesium serum levels (sMg) and GFR markers: serum levels of creatinine (sCr), Cockroft-Gault (ClCG) and Modification Diet of Renal Disease (MDRD) formulae were recorded before each cycle, and 3 weeks after the sixth course.


RESULTS
41 EOC patients were randomised and 40 were eligible. sMg varied significantly between the supplemented and placebo groups (p<0.0001). The control group showed a significantly greater decrease of GFR assessed by: sCr (p=0.0069), ClCG (p=0.0077) and MDRD (p=0.032) formulae compared with the magnesium supplemented group.


CONCLUSIONS
These results demonstrate the nephroprotective effect of magnesium supplementation during chemotherapy with cisplatin.
Bodnar
Lubomir
L
Department of Oncology, Military Institute of The Health Services, Warsaw, Poland. lubo@esculap.pl
Wcislo
Gabriel
G
Gasowska-Bodnar
Agnieszka
A
Synowiec
Agnieszka
A
Szarlej-Wcisło
Katarzyna
K
Szczylik
Cezary
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008274:Magnesium / Q000627:therapeutic use*; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D012076:Renal Agents / Q000627:therapeutic use*
D012076:Renal Agents; C005479:magnesium carbonate; D008278:Magnesium Sulfate; D008274:Magnesium; D017239:Paclitaxel; D002945:Cisplatin